The Lancet Oncology in conversation with artwork

Rosie Bradley on early-stage breast cancer treatment

The Lancet Oncology in conversation with

English - February 28, 2022 23:00 - 4 minutes - 3.16 MB - ★★★★★ - 1 rating
Medicine Health & Fitness Education cancer radiotherapy chemotherapy mrna Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Yi-Long Wu and Caicun Zhou on non-small-cell lung cancer

Next Episode: Lisa Iezzoni on disabilities and cancer, and Jordan Marchak on mental health problems in young cancer survivors

Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.

Read the full article:
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv